ATE290397T1 - Formulierung fur die wundheilung mit menschlichem plasma fibronektin - Google Patents

Formulierung fur die wundheilung mit menschlichem plasma fibronektin

Info

Publication number
ATE290397T1
ATE290397T1 AT96917308T AT96917308T ATE290397T1 AT E290397 T1 ATE290397 T1 AT E290397T1 AT 96917308 T AT96917308 T AT 96917308T AT 96917308 T AT96917308 T AT 96917308T AT E290397 T1 ATE290397 T1 AT E290397T1
Authority
AT
Austria
Prior art keywords
human plasma
fibronectin
wound healing
formulation
plasma fibronectin
Prior art date
Application number
AT96917308T
Other languages
English (en)
Inventor
Andre Beaulieu
Original Assignee
Andre Beaulieu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andre Beaulieu filed Critical Andre Beaulieu
Application granted granted Critical
Publication of ATE290397T1 publication Critical patent/ATE290397T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/60Liquid-swellable gel-forming materials, e.g. super-absorbents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028Polypeptides; Proteins; Degradation products thereof
    • A61L26/0047Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061Use of materials characterised by their function or physical properties
    • A61L26/008Hydrogels or hydrocolloids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96917308T 1995-06-07 1996-06-06 Formulierung fur die wundheilung mit menschlichem plasma fibronektin ATE290397T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/488,253 US5641483A (en) 1995-06-07 1995-06-07 Wound healing formulations containing human plasma fibronectin
PCT/CA1996/000384 WO1996040221A1 (en) 1995-06-07 1996-06-06 Wound healing formulations containing human plasma fibronectin

Publications (1)

Publication Number Publication Date
ATE290397T1 true ATE290397T1 (de) 2005-03-15

Family

ID=23938969

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96917308T ATE290397T1 (de) 1995-06-07 1996-06-06 Formulierung fur die wundheilung mit menschlichem plasma fibronektin

Country Status (8)

Country Link
US (1) US5641483A (de)
EP (2) EP0784481B1 (de)
AT (1) ATE290397T1 (de)
CA (1) CA2197244A1 (de)
DE (1) DE69634430T2 (de)
ES (1) ES2236733T3 (de)
PT (1) PT784481E (de)
WO (1) WO1996040221A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583114A (en) 1994-07-27 1996-12-10 Minnesota Mining And Manufacturing Company Adhesive sealant composition
US6528483B2 (en) * 1995-06-07 2003-03-04 André Beaulieu Method of producing concentrated non-buffered solutions of fibronectin
US5821220A (en) * 1995-06-07 1998-10-13 Andre Beaulieu Method of producing concentrated non-buffered solutions of fibronectin
US7112320B1 (en) * 1995-06-07 2006-09-26 Andre Beaulieu Solid wound healing formulations containing fibronectin
US20030105007A1 (en) * 1995-06-07 2003-06-05 Andre Beaulieu PDGF-betabeta and fibronectin combined in a solid wound dressing for the treatment of wounds
US6194378B1 (en) 1998-02-18 2001-02-27 The Research Foundation Of State University Of New York Fibronectin peptides-based extracellular matrix for wound healing
US6497893B1 (en) 1999-06-30 2002-12-24 Kimberly-Clark Worldwide, Inc. Silk protein treatment composition and treated substrate for transfer to skin
CO5150202A1 (es) 1998-12-31 2002-04-29 Kimberly Clark Co Composicion de tisu facial y metodo para usarla para el secuestro de irritantes de la piel de la secrecion nasal
US7261881B1 (en) 1999-05-20 2007-08-28 Yale University Modulation of angiogenesis and wound healing
US6506394B1 (en) 1999-06-30 2003-01-14 Kimberly-Clark Worldwide, Inc. Delivery of a botanical extract to a treated substrate for transfer to skin
US6500443B1 (en) 1999-06-30 2002-12-31 Kimberly-Clark Worldwide, Inc. Delivery of a sacrificial substrate to inhibit protease permeation into skin
AU781865B2 (en) * 1999-08-20 2005-06-16 Andre Beaulieu Solid wound healing formulations containing fibronectin
KR100469661B1 (ko) * 2000-03-28 2005-02-02 한스바이오메드 주식회사 이식용 무세포 진피층 및 이의 제조방법
US6503524B1 (en) 2000-06-16 2003-01-07 Kimberly-Clark Worldwide, Inc. Delivery of a skin health benefit agent to a treated substrate for transfer to skin
US7829072B2 (en) * 2000-07-14 2010-11-09 Carter Daniel C Serum albumin compositions for use in cleansing or dermatological products for skin or hair
GB0119476D0 (en) * 2001-08-09 2001-10-03 Novartis Forschungsstiftlung Z Anti-tumour agents and method of identifying anti-tumour agents
RU2308954C2 (ru) * 2002-05-09 2007-10-27 Медиджинез Фармацевтическая композиция для лечения ран, содержащая плазму или сыворотку крови
JP2004075661A (ja) * 2002-06-18 2004-03-11 Shiseido Co Ltd 表皮基底膜ケアを特徴とする皮膚外用剤、皮膚基底膜構造形成促進剤および人工皮膚の製造方法
US7634668B2 (en) 2002-08-22 2009-12-15 Nvidia Corporation Method and apparatus for adaptive power consumption
AU2003901515A0 (en) * 2003-04-02 2003-04-17 Norika Holdings Sterilisation process for pharmaceutical product
US20070275874A1 (en) * 2004-09-03 2007-11-29 Yale University Use of Leptin in Wound Healing
US7858126B2 (en) * 2006-08-31 2010-12-28 Trinity Laboratories Inc. Derivatives of sandalwood oil and santalols for treating cold sores and herpes
US8700925B2 (en) 2009-09-01 2014-04-15 Nvidia Corporation Regulating power using a fuzzy logic control system
RU2463063C1 (ru) * 2011-07-06 2012-10-10 Федеральное государственное учреждение "Российский научный центр "Восстановительная травматология и ортопедия" имени академика Г.А. Илизарова" Министерства здравоохранения и социального развития Российской Федерации Способ получения средства для стимуляции репаративной регенерации кожного покрова
US20130017227A1 (en) * 2011-07-15 2013-01-17 Lambert Jr Cary Jake Wound healing compositions and associated methods
WO2015075406A1 (en) * 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers
EP3334441B1 (de) 2015-08-13 2021-06-16 Kamada Ltd. Aus cohn-fraktions-paste abgeleitete zusammensetzungen verwendung davon
US10590184B2 (en) * 2016-09-26 2020-03-17 National Yang-Ming University Process for a preparation of the modified porcine plasma fibronectin for enhance wound healing

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4455300A (en) * 1980-03-05 1984-06-19 Cutter Laboratories, Inc. Fibronectin compositions
US4925924A (en) * 1984-03-27 1990-05-15 University Of Medicine And Dentistry Of New Jersey Biocompatible synthetic and collagen compositions having a dual-type porosity for treatment of wounds and pressure ulcers and therapeutic methods thereof
JPS61103836A (ja) * 1984-10-24 1986-05-22 Green Cross Corp:The フイブロネクチン製剤
US5112608A (en) * 1987-03-13 1992-05-12 Incyte Pharmaceuticals Use of protease nexin-I to mediate wound healing
US4837019A (en) * 1986-08-11 1989-06-06 Charles Of The Ritz Group Ltd. Skin treatment composition and method for treating burned skin
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US5053388A (en) * 1987-11-09 1991-10-01 Chiron Ophthalmics, Inc. Wound healing composition and method
JP2561113B2 (ja) * 1988-02-16 1996-12-04 寳酒造株式会社 細胞接着活性ポリペプチド
US4973466A (en) * 1988-06-21 1990-11-27 Chiron Ophthalmics, Inc. Wound-healing dressings and methods
US5124155A (en) * 1988-06-21 1992-06-23 Chiron Ophthalmics, Inc. Fibronectin wound-healing dressings
JP2561131B2 (ja) * 1988-06-30 1996-12-04 寳酒造株式会社 細胞接着活性ポリペプチド
FI86339C (fi) * 1988-12-09 1992-08-10 Ari Tuomi Diffusionscell foer undersoekning av salvor och liknande.
JPH04503951A (ja) * 1988-12-20 1992-07-16 ラ ホヤ キャンサー リサーチ ファウンデーション 創傷治癒に活性のあるポリペプチド―ポリマー複合体
WO1990008833A1 (en) * 1989-02-02 1990-08-09 Massachusetts Institute Of Technology Expression of recombinant fibronectin in genetically engineered cells
GB8909916D0 (en) * 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
ATE92107T1 (de) * 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5155038A (en) * 1990-02-22 1992-10-13 W. R. Grace & Co.-Conn. Use of thrombospondin to promote wound healing
GB9101191D0 (en) * 1991-01-18 1991-02-27 Univ London Wound treatment
GB9101183D0 (en) * 1991-01-18 1991-02-27 Univ London Depot formulations

Also Published As

Publication number Publication date
EP1563844A3 (de) 2007-03-14
EP0784481A1 (de) 1997-07-23
DE69634430D1 (de) 2005-04-14
EP1563844A2 (de) 2005-08-17
EP0784481B1 (de) 2005-03-09
ES2236733T3 (es) 2005-07-16
CA2197244A1 (en) 1996-12-19
PT784481E (pt) 2005-07-29
US5641483A (en) 1997-06-24
WO1996040221A1 (en) 1996-12-19
DE69634430T2 (de) 2006-01-05

Similar Documents

Publication Publication Date Title
DE69634430D1 (de) Formulierung fur die wundheilung mit menschlichem plasma fibronektin
FR2782269B1 (fr) Composition cosmetique et/ou dermatologique contenant de l'acide salicylique ou un derive d'acide salicylique et son utilisation
PT859596E (pt) Formulacoes em gel contendo factores de crescimento
DE59209658D1 (de) Pharmazeutische zusammensetzung zur wund-, narben- und keloidbehandlung
ES2058517T3 (es) Composicion cosmetica.
ZA904971B (en) Stable,cosmetically acceptable topical gel formulation and method of treatment for acne
ATE209032T1 (de) Retinoid-formulierungen in porösen mikrokugeln für verringerte irritation und verbesserte stabilität
ES2175295T3 (es) Uso de un poliholosido en una composicion destinada a favorecer la descamcion de la piel y su composicion.
AU674142B2 (en) Use of cosmetic composition
DE68912195D1 (de) Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis.
CA2411922A1 (en) Composition for pain mediation and apparatus and method of use thereof
ES2063250T3 (es) Uso de la trombospondina para facilitar la curacion de las heridas.
DE3685696D1 (de) Melatoninhaltige mittel sowie deren verwendungen.
ES2113222T3 (es) Utilizacion de derivados de acido benzoico para estimular el proceso de renovacion epidermica y tratar la piel.
DK0951294T3 (da) Sårhelende formuleringer indeholdende humanplasmafibronectin
EP0801945A3 (de) Verwendung von Glucosiden von Ferulasäure als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen
BR9809351A (pt) Tecido de bainha dérmica na cura de lesões
ATE182784T1 (de) Hydrogel für die applikation von therapeutischen und/oder kosmetischen wirkstoffen an die haut
NZ336600A (en) Use of dichlorobenzyl alcohol for preparing a preparation for topical treatment of inflammation
ATE120959T1 (de) Wasserlösliche vitamin a-zubereitungen und deren verwendung bei der hautbehandlung.
DE3784738D1 (de) Topische vorstufen von arzneimitteln zur behandlung von akne und hautkrankheiten.
DE68905076D1 (de) Pharmazeutische zusammensetzung fuer die behandlung von hautwunden.
DE69825322D1 (de) Topische carbamazepin-formulierungen und deren verwendung
IT9048186A0 (it) Impiego teperautico della ranitidina nella cura di ferite interessantila cute e i tessuti sottostanti
IL122358A0 (en) Stable gel formulation for topical treatment of skin conditions

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0784481

Country of ref document: EP

REN Ceased due to non-payment of the annual fee